COMPANY PROFILE

Plasmagen

Explore full profile

Health & quality of life of patients

Bengaluru, IndiaHealth

Valuation $100–250M Last recorded · 2025

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Plasmagen

PlasmaGen BioSciences is an Indian biopharmaceutical organization headquartered in Bengaluru, specializing in Plasma Protein and Specialty Care Therapy. The company addresses the significant gap between the availability of plasma specialty care products and the immense need for these therapies in India and other developing economies. PlasmaGen's core mission is to enhance the availability of these critical products for patients, ensuring a safe and consistent supply. The company operates in several countries, including Sri Lanka, Bangladesh, and El Salvador, with plans to expand into other selected developing economies.

PlasmaGen serves healthcare providers and patients who require plasma-based therapies. The company operates in the biopharmaceutical market, focusing on niche therapy segments. Its business model revolves around sourcing, manufacturing, and marketing plasma products. Revenue is generated through the sale of these specialized therapies to healthcare institutions and providers.

PlasmaGen is committed to establishing collaborative partnerships to further its mission of providing safe plasma products. The company employs a specialized team dedicated to plasma product sourcing, manufacturing, and marketing functions.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Headquarters: Bengaluru, India
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sector: Health, Hard Tech
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES D✓Equity / VC	Dec 2025	$17M	$67M	Undisclosed	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Plasmagen website traffic

Latest recorded traffic for Plasmagen is 1.6K monthly website visits, up 33.3% over the last three months.

Latest monthly visits1.6K 3-month web change+33.3%

Monthly website visitsJan 2026–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GTGemini TherapeuticsInnovative therapies targeting genetically defined subpopulations in dry AMD and related diseases	Cambridge, United States	Operational	1	$45M	$217M
DMDigma MedicalA clinical stage medical device company revolutionizing treatment of Type-2 Diabetes & NASH	Giv'at Shmuel, Israel	Operational
ANAnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market	Dongcheng District, China	Operational
STStorm TherapeuticsSmall molecule therapies targeting RNA modifying enzymes	Cambridge, United Kingdom	Operational
MOMorphogen-IXEngineered protein therapeutics for pulmonary arterial hypertension	Babraham, United Kingdom	Acquired
STSpur TherapeuticsGene therapies for Gaucher, Parkinson's, and cardiovascular diseases	Stevenage, United Kingdom	Acquired
ATAt-biotechHealth care company that creates technological automation and safety solutions for the healthcare sector	Madrid, Spain	Operational
MLMedGenome LabsA genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome	Foster City, United States	Operational